they are still around From who the next step will come first, spectrum or endo?
from the transcript:
Joseph Pantginis - Roth Capital Partners, LLC, Research Division
Okay. And then just lastly, real quickly. I'm just curious if there's any updates with regard to the data analysis that were ongoing behind the scenes for apaziquone or any potential plans between you and Allergan.
Rajesh C. Shrotriya - Chairman, Chief Executive Officer, President, Chairman of Placement Committee and Chairman of Product Acquisition Committee
Yes. So I think as we have said before, Joe, that we have -- we are planning to have a meeting with the FDA sometime in the future and see what strategy we can develop. As you know, that when the 2 studies are combined, then the data is highly significant in favor of apaziquone. However, standalone 2 studies do not make the feedback view of less than 05. So at this time, this is work in progress, and we'll keep you posted.
https://seekingalpha.com/article/988451-spectrum-pharmaceuticals-management-discusses-q3-2012-results-earnings-call-transcript?part=single